Mr. Sanket Pawar, Mr.Bhavesh Dandagvhal, Mr. Prasad Nikam, Miss. Mayuri Salave,
Miss. Vidya Ekhande, Miss. Pallavi Pagar, Miss. Sakshi Somani, Dr. Sanjay J. Kshirsagar, Dr. Eknath D. Ahire, Dr. Smita Kakad
Department of Pharmaceutics, METs institute of Pharmacy, Bhujbal Knowledge City, Adgaon, Govardhan, Nashik, Maharashtra, India.
A Review; Prevalence, Causes and Treatment of Gout and Hyperuricemia
Authors
Abstract
The purpose of this paper is to conduct a critical analysis of the data regarding the
various therapeutic approaches for the management of hyperuricemia. In affluent nations, the
burden of gout has increased due to an increase in the prevalence of both hyperuricemia and
gout in recent decades. Imaging methods have shown to be helpful in identifying urate
deposition even before the onset of clinical symptoms. This allows for the assessment of the
degree of deposition and the monitoring of crystal depletion objectively during urate-lowering
therapy. Treating to target is becoming a more popular method for treating a variety of
illnesses. Consequently, distinct goals have been suggested for various phases of the disease
burden and therapy phases. The ultimate strategic goal, towards which all efforts should be
directed, is the total dissolution of urate crystals in tissues, thereby preventing additional
symptoms and structural harm to the musculoskeletal structures involved.
Keywords: Crystal deposition disease; Gout; Hyperuricemia; Uric acid